Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements Active Not Recruiting Phase 2 Trials for Varlilumab (DB11930)

Also known as: Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

IndicationStatusPhase
DBCOND0131475 (Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03038672Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell LymphomasTreatment